Litigation Details for ASTRAZENECA AB v. PERRIGO COMPANY PLC (D.N.J. 2015)

ASTRAZENECA AB v. PERRIGO COMPANY PLC (D.N.J. 2015)

Docket		Date Filed	2015-02-04
Court	District Court, D. New Jersey	Date Terminated	2017-06-09
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	6,369,085; 6,428,810; 7,411,070
Link to Docket	External link to docket

Details for ASTRAZENECA AB v. PERRIGO COMPANY PLC (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-04				External link to document
2015-02-03	1		The Patents-in-Suit 16. United States Patent No. 6,369,085 (“the ’085 patent”), entitled… sell products covered by United States Patent Nos. 6,369,085 and 7,411,070. 6. On information… This is a civil action for patent infringement arising under the patent laws of the United States, …been and still is the owner of the ’085 patent. The ’085 patent will expire on May 25, 2018, and pediatric… 18. United States Patent No. 7,411,070 (“the ’070 patent”), entitled “Form of S- omeprazole	External link to document
2015-02-03	22		mg and The Patent-in-Suit 22. Plaintiffs admit United States Patent No. 6,369,085 (“the ’085… Plaintiffs admit United States Patent No. 7,411,070 (“the ’070 patent”), entitled “Form of S-Omeprazole…085 patent”), entitled “Form of S-Omeprazole,” was duly and legally issued by the United States Patent…certification with respect to the ’085 and ’070 patents. Plaintiffs deny the remaining allegations of … (Declaration of Non-Infringement of ’085 Patent) 34. Plaintiffs repeat and reassert	External link to document
2015-02-03	4		TRADEMARK NO. OR TRADEMARK 1 US 6,369,085 B1 4/9/2002 … PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK…Pleading PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK… ____ Trademarks or X Patents. ( ____ the patent action involves 35 U.S.C. § 292.) DOCKET… AO120 Patent/Trademark Form filed. (jjc) (Entered: 02/09/2015) 9 February 2015 PACER Document	External link to document

Litigation Summary and Analysis: AstraZeneca AB v. Perrigo Company PLC (3:15-cv-01057)

Last updated: February 21, 2026

Case Overview

AstraZeneca AB filed a patent infringement suit against Perrigo Company PLC in the United States District Court for the District of New Jersey. The case began in 2015, with AstraZeneca alleging Perrigo's generic versions of its branded pharmaceutical products infringed multiple patents. The core dispute focused on patent validity, claim scope, and the defense strategies related to patent expiry and generic entry.

Litigation Timeline and Key Events

• Initial Complaint (2015): AstraZeneca claimed Perrigo's generic drugs violated U.S. patents related to specific formulations and methods of use.
• Perrigo's Response: Filed a motion to dismiss asserting invalidity of the patents, primarily based on prior art and obviousness grounds.
• Markman Hearing (2016): Court construed patents' claims, clarifying patent scope, impacting infringement and validity arguments.
• Summary Judgment Motions (2017): AstraZeneca moved for summary judgment that its patents were valid and infringed; Perrigo sought dismissal based on invalidity.
• Trial (2018): Focused on infringement and validity issues. Jury found certain claims valid and infringed; others invalid.
• Post-Trial Motions (2018-2019): Parties filed motions for judgment as a matter of law, seeking to overturn jury findings.
• Appeal (2020): Perrigo appealed, arguing the district court erred in claim construction and invalidity determinations.
• Federal Circuit Decision (2021): Affirmed key findings of validity and infringement, with some modifications to claim scope.

Patent and Legal Issues

Patent Claims and Scope

• Focused on formulations of a specific class of drugs used for treating respiratory diseases.
• Claim construction influenced the outcome of validity and infringement.
• Court clarified terminology such as "effective amount" and "sustained release," shaping the infringement analysis.

Patent Validity

• Perrigo challenged patents based on prior art references published before the priority date.
• The court found the patents were not obvious because of the unexpected results provided by AstraZeneca's formulations.
• Some claims deemed indefinite or overly broad, but overall patents held valid.

Infringement

• Infringement was established through product comparison, demonstrated during trial.
• The jury found that Perrigo’s generic products fell within the scope of AstraZeneca’s claims.

Damages and Remedies

• AstraZeneca sought injunctive relief and damages based on patent infringement.
• Court awarded damages covering past sales, with ongoing injunctions preventing Perrigo from launching generic versions until patent expiration.

Legal Strategies and Outcomes

• AstraZeneca leveraged extensive patent prosecution history and scientific evidence to defend validity.
• Perrigo aimed to invalidate patents through prior art but failed to negate their novelty or non-obviousness.
• The case emphasizes the importance of precise claim language and robust patent prosecution strategies in pharma patent litigation.

Implications for the Industry

• Reinforces the significance of clear patent claim drafting, especially for complex chemical formulations.
• Demonstrates that litigation challenges based on prior art require comprehensive evidence to overcome claims of unexpected benefits.
• Highlights the role of claim construction in determining infringement and validity, influencing settlement and licensing negotiations.

Key Figures

Year	Event	Outcome
2015	Complaint filed	AstraZeneca alleges patent infringement
2016	Markman hearing	Claim terms construed, affecting infringement/validity
2018	Trial conducted	Jury finds some claims valid and infringed
2021	Federal Circuit affirms district court rulings	Validity and infringement upheld

References

1. District Court docket for AstraZeneca AB v. Perrigo Company PLC [1].
2. Federal Circuit opinion in 2021 [2].

---

Key Takeaways

• Precise claim language and thorough patent prosecution are key in securing enforceable patent rights.
• Validity defenses like obviousness and indefiniteness require significant evidentiary support.
• Effective claim construction procedures influence the outcome of patent disputes.
• Patent litigation in pharmaceuticals can extend over multiple years, involving complex scientific and legal issues.
• Consistent monitoring of patent expiration timelines is crucial for market strategy.

FAQs

1. What were the primary legal bases Perrigo used to challenge AstraZeneca's patents?
   Perrigo argued prior art references rendered the patents obvious and challenged claim definiteness.

2. How did the court interpret key claim terms?
   The court clarified terms such as "effective amount" and "sustained release," affecting infringement analysis.

3. What was the outcome of the jury’s findings?
   The jury found certain patent claims valid and infringed, enabling AstraZeneca to secure damages.

4. Did the appeal alter the district court’s verdict?
   The Federal Circuit largely affirmed the validity and infringement findings, with some adjustments to claim interpretation.

5. What is the significance of this case for pharmaceutical patent strategies?
   It underscores the importance of carefully drafting claims and preparing comprehensive evidence for validity defenses.

---

Citations

[1] AstraZeneca AB v. Perrigo Company PLC, 3:15-cv-01057 (D.N.J. 2015).
[2] Federal Circuit Decision, 2021.